Zoledronic acid for chronic kidney disease-associated osteoporosis.

BACKGROUND

Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.

CASE PRESENTATION: We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.

CONCLUSION

This case highlights the potential role of bisphosphonates in chronic kidney disease-associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.